Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 2Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2

Interventions

Radiosurgery 7Oxaliplatin 7Docetaxel 7Paclitaxel 5Fluorouracil 5Nivolumab 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Carboplatin 4Capecitabine 4Trastuzumab 3Radiotherapy 3Radiation 3Leucovorin 3Erlotinib Hydrochloride 3Cyclophosphamide 3Cetuximab 3Bevacizumab 3spartalizumab 2sipuleucel-T 2repotrectinib 2pembrolizumab 2pazopanib 2orteronel 2fludarabine 2atezolizumab 2aldesleukin 2Temozolomide 2Surveys and Questionnaires 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasm Metastasis × orteronel × Clear all
NCT01658527 2016-06-10

TAK-700 in Castration Resistant Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02054793 2014-07-23

Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)

Johns Hopkins University

Phase 1/2 Withdrawn
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡